Number: P2C 8317 Principal Investigator: Adkins, Douglas
Title: Phase I/II trial of Cediranib alone or Cediranib and Lenalidomide in iodine 131-refractory differentiated thyroid cancer
Description: The uprpose of this study is to learn about the side effects and determine the best dose of cediranib maleate when given with or without lenalidomide and to see how well they work in treating patients with thyroid cancer....MORE
 Number: CALGB A091305 Principal Investigator: Adkins, Douglas
Title: Phase 2 Randomized Study of Efatutazone, an Oral PPAR Agonist, In Combination with Paclitaxel versus Paclitaxel in Patients with Advanced Anaplastic Thyroid Cancer
Description: The purpose of this study is to compare any good and bad effects of using efatutazone along with the usual chemotherapy (Paclitaxel)to using the usual chemotherapy(Paclitaxel)alone....MORE
 Number: 201308046 Principal Investigator: Adkins, Douglas
Title: A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™) 300 mg in Patients with Papillary or Poorly Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy
Description: The purpose of this study is to investigate if vandetanib can help keep thyroid cancer from growing, or progressing. This study will also explore which patients respond best to vandetanib, how vandetanib works, and how vandetanib is tolerated in patients with thyroid cancer. This study will also me...MORE
 Number: 201301163 Principal Investigator: Okuyemi, Oluwafumnilola
Title: Impact of Multimedia-based Patient Education on Patient Satisfaction Scores in an Otolaryngology Practice Setting
Description: The aim of this study is to assess the improvement in patient satisfaction scores that can be obtained by incorporating LUMA ENT™, a disease-specific multimedia patient education software, into the treatment decisions for thyroid disorders....MORE